Filtered By:
Specialty: Drugs & Pharmacology

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 3220 results found since Jan 2013.

Versatile electrostatically assembled polymeric siRNA nanovectors: can they overcome the limits of siRNA tumor delivery?
Publication date: Available online 11 June 2019Source: International Journal of PharmaceuticsAuthor(s): S. Ben Djemaa, E. Munnier, I. Chourpa, E. Allard-Vannier, S. DavidAbstractThe application of small interfering RNA (siRNA) cancer therapeutics is limited by several extra- and intracellular barriers including the presence of ribonucleases that degrade siRNA, the premature clearance, the impermeability of the cell membrane, or the difficulty to escape endo-lysosomal degradation. Therefore, several delivery systems have emerged to overcome these limitations and to successfully deliver siRNA to the tumor site. This review i...
Source: International Journal of Pharmaceutics - June 21, 2019 Category: Drugs & Pharmacology Source Type: research

Anti-RelA siRNA-Encapsulated Flexible Liposome with Tight Junction-Opening Peptide as a Non-invasive Topical Therapeutic for Atopic Dermatitis.
Abstract Small interfering RNA (siRNA) has been proposed as a novel treatment for atopic dermatitis (AD) because it suppresses sequence-specific mRNA expression. Indeed siRNA-based therapy achieves an almost complete cure with fewer side effects than currently available treatments. However, the tight junctions in the granular layer of the epidermis in the atopic skin are barriers to siRNA delivery. We previously reported the potential clinical utility of AT1002, a peptide that opens tight junctions. In the present study, we evaluated a topical siRNA-based therapy for AD using AT1002 in combination with a flexible ...
Source: Biological and Pharmaceutical Bulletin - July 3, 2019 Category: Drugs & Pharmacology Authors: Ibaraki H, Kanazawa T, Kurano T, Oogi C, Takashima Y, Seta Y Tags: Biol Pharm Bull Source Type: research

High siRNA loading powder for inhalation prepared by co-spray drying with human serum albumin
This study aimed to prepare inhalable siRNA powder formulations that contained high siRNA loading of over 6% w/w by spray drying, with human serum albumin (HSA) investigated as a dispersion enhancer to improve the aerosol performance. The effect of siRNA, HSA and solute concentrations in the formulations were evaluated systemically using factorial analyses. All the spray dried siRNA powders exhibited excellent aerosol performance with fine particle fraction (FPF) consistently over 50% in all the formulations. An enrichment of HSA on the particle surface was observed. Surface corrugation was more prominent as the HSA compos...
Source: International Journal of Pharmaceutics - November 1, 2019 Category: Drugs & Pharmacology Source Type: research

Enhanced anticancer effect of doxorubicin by TPGS-coated liposomes with Bcl-2 siRNA-corona for dual suppression of drug resistance
In conclusion, TPGS-coated cationic liposomes with Bcl-2 siRNA corona had the capacity to inhibit MDR dual-pathways and subsequently improved the anti-tumor activity of the chemotherapeutic agent co-delivered to a level that cannot be achieved by inhibiting a MDR single way.Graphical abstract
Source: Asian Journal of Pharmaceutical Sciences - November 13, 2019 Category: Drugs & Pharmacology Source Type: research

SiRNA-circFARSA-loaded porous silicon nanomaterials for pancreatic cancer treatment via inhibition of CircFARSA expression
In this study, we designed and synthesized a small interfering RNA (siRNA, named siRNA-circFARSA), which specifically inhibits circFARSA expression. Using liposomes and porous silicon nanoparticles (pSiNPs) as siRNA delivery system, we prepared liposome-siRNA-circFARSA and pSiNP-PEI-siRNA-circFARSA and investigated their anti-cancer mechanism by quantitative real-time PCR and western blotting. Cell proliferation curves and transwell migration assays were performed to investigate the effect of siRNAs proliferation and migration capabilities of cancer cells. Patient-derived tumor xenograft mouse models were used to investiga...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 1, 2022 Category: Drugs & Pharmacology Authors: Huixiao Yuan Xin Huang Qingqing Li Cici Luo Chenyu Lin Shuxian Zhang Yaguang Zhang Zhilin Yan Ning Du Zhongmin Liu Hua Jiang Bingdi Chen Source Type: research

The Development of Ternary Nanoplexes for Efficient siRNA Delivery.
Abstract Targeted posttranscriptional gene silencing by RNA interference (RNAi) has garnered considerable interest as an attractive new class of drugs for several diseases, such as cancer. Chitosan and protamine are commonly used as a vehicle to deliver and protect small interfering RNA (siRNA), but the strong interaction still remains to be modulated for efficient siRNA uptake and silencing. Therefore, in this study, ternary nanoplexes containing chitosan and protamine were designed to substantially enhance the siRNA efficiency. Binary and ternary nanoplexes were prepared at different the ratios of moles of the a...
Source: Biological and Pharmaceutical Bulletin - October 3, 2013 Category: Drugs & Pharmacology Authors: Salva E, Turan SO, Akbuğa J Tags: Biol Pharm Bull Source Type: research

TPP-dendrimer nanocarriers for siRNA delivery to the pulmonary epithelium and their dry powder and metered-dose inhaler formulations
Publication date: 15 July 2017 Source:International Journal of Pharmaceutics, Volume 527, Issues 1–2 Author(s): Elizabeth Bielski, Qian Zhong, Hamad Mirza, Matthew Brown, Ashura Molla, Teresa Carvajal, Sandro R.P. da Rocha The regulation of genes utilizing the RNA interference (RNAi) mechanism via the delivery of synthetic siRNA has great potential in the treatment of a variety of lung diseases. However, the delivery of siRNA to the lungs is challenging due to the poor bioavailability of siRNA when delivered intraveneously, and difficulty in formulating and maintaining the activity of free siRNA when delivered directly ...
Source: International Journal of Pharmaceutics - June 1, 2017 Category: Drugs & Pharmacology Source Type: research

siRNA-Mediated RNA Interference in Precision-Cut Tissue Slices Prepared from Mouse Lung and Kidney
In conclusion, thisex vivo transfection model can be used to evaluate the effects of siRNA in relevant biological environments.
Source: The AAPS Journal - September 11, 2017 Category: Drugs & Pharmacology Source Type: research

Strategies, design, and chemistry in siRNA delivery systems.
Abstract Emerging therapeutics that utilize RNA interference (RNAi) have the potential to treat broad classes of diseases due to their ability to reversibly silence target genes. In August 2018, the FDA approved the first siRNA therapeutic, called ONPATTRO™ (Patisiran), for the treatment of transthyretin-mediated amyloidosis. This was an important milestone for the field of siRNA delivery that opens the door for additional siRNA drugs. Currently, >20 small interfering RNA (siRNA)-based therapies are in clinical trials for a wide variety of diseases including cancers, genetic disorders, and viral infections. T...
Source: Advanced Drug Delivery Reviews - May 14, 2019 Category: Drugs & Pharmacology Authors: Dong Y, Siegwart DJ, Anderson DG Tags: Adv Drug Deliv Rev Source Type: research

Recent advances in siRNA delivery mediated by lipid-based nanoparticles.
Abstract Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the treatment of broad-spectrum intractable diseases. However, its unfavorable properties such as easy degradation in the blood and negative-charge density are still a formidable barrier for clinical use. For disruption of this barrier, siRNA delivery technology has been significantly advanced in the past two decades. The approval of Patisiran (ONPATTRO™) for the treatment of transthyretin-mediated amyloidosis, the first approved siRNA drug, is a most important milestone. Since lipid-based nanoparticles (LNPs) are used in Pa...
Source: Advanced Drug Delivery Reviews - August 4, 2020 Category: Drugs & Pharmacology Authors: Yonezawa S, Koide H, Asai T Tags: Adv Drug Deliv Rev Source Type: research

Design and Invitro Characterization of Green Synthesized Magnetic Nanoparticles Conjugated with Multitargeted Poly Lactic Acid Copolymers for Co-delivery of siRNA and Paclitaxel
CONCLUSION: Conjugation of both folic acid and T7-peptide on the surface of micelles compared to separate conjugation of one of these ligands, increased the efficiency of drug and siRNA delivery to breast cancer cells.PMID:34520835 | DOI:10.1016/j.ejps.2021.106007
Source: European Journal of Pharmaceutical Sciences - September 14, 2021 Category: Drugs & Pharmacology Authors: Amin Amani Mohammad Dustparast Mehran Noruzpour Rasool Asghari Zakaria Hossein Ali Ebrahimi Source Type: research